| 2023-12-12 |
复牌提示：
2023-12-11 16:27:02 停牌，复牌日期 2023-12-11 17:16:00
|
| 2023-11-21 |
详情>>
股本变动：
变动后总股本1777.55万股
|
| 2023-11-21 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-2.74美元,归母净利润-4781.5万美元,同比去年增长75.56%
|
| 2023-08-10 |
详情>>
业绩披露：
2023年中报每股收益-1.6美元,归母净利润-2721万美元,同比去年增长8.94%
|
| 2023-08-10 |
财报披露：
美东时间 2023-08-10 盘后发布财报
|
| 2023-05-11 |
详情>>
业绩披露：
2023年一季报每股收益-0.51美元,归母净利润-808.3万美元,同比去年增长53.67%
|
| 2023-03-31 |
详情>>
业绩披露：
2022年年报每股收益-15.17美元,归母净利润-2.23亿美元,同比去年增长34.61%
|
| 2022-12-29 |
详情>>
业绩披露：
2022年三季报(累计)每股收益-13.41美元,归母净利润-1.96亿美元,同比去年增长-6128.75%
|
| 2022-12-05 |
详情>>
拆分方案：
每10.0000合并分成1.0000股
|
| 2022-11-15 |
股东大会：
将于2022-12-05召开股东大会
会议内容 ▼▲
- 1.To elect three Class I directors to hold office until the 2025 annual meeting and until their respective successors are elected and qualified.
2.To ratify the appointment of BPM LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022.
3.To approve an amendment to our Second Amended and Restated Certificate of Incorporation to effect a reverse stock split of our Common Stock, at a specific ratio within a range of 4:1 to 10:1 to be fixed by the Board.
|
| 2022-08-15 |
详情>>
业绩披露：
2022年中报每股收益-0.21美元,归母净利润-2988.3万美元,同比去年增长16.37%
|
| 2022-05-31 |
股东大会：
将于2022-06-28召开股东大会
会议内容 ▼▲
- 1.To elect three Class I directors to hold office until the 2025 annual meeting and until their respective successors are elected and qualified.
2.To ratify the appointment of Plante & Moran, PLLC as our independent registered public accounting firm for the fiscal year ending December 31, 2022.
3.To transact such other business as may properly come before the meeting or any adjournment or postponement of the meeting.
|
| 2022-05-23 |
详情>>
业绩披露：
2022年一季报每股收益-0.12美元,归母净利润-1744.5万美元,同比去年增长-491.56%
|
| 2022-04-18 |
详情>>
业绩披露：
2021年年报每股收益-3.19美元,归母净利润-3.41亿美元,同比去年增长-15500.32%
|
| 2021-11-10 |
详情>>
业绩披露：
2021年三季报(累计)每股收益-0.03美元,归母净利润-314.1万美元,同比去年增长-196.32%
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-08-12 |
详情>>
业绩披露：
2021年中报每股收益-0.43美元,归母净利润-3573.4万美元,同比去年增长-6529.68%
|
| 2021-05-13 |
股东大会：
将于2021-06-04召开股东大会
会议内容 ▼▲
- 1.The UpHealth Business Combination Proposal-To approve and adopt the UpHealth Business Combination Agreement, dated as of November 20, 2020 (as subsequently amended on January 29, 2021, March 23, 2021 and April 23, 2021 and as it may be further amended from time to time, the “UpHealth Business Combination Agreement”) by and among the Company, its wholly owned subsidiary, UpHealth Merger Sub, Inc. (“UpHealth Merger Sub”), and UpHealth Holdings, Inc. (“UpHealth”), a copy of which is attached to this proxy statement/prospectus as Annex A, and approve the transactions contemplated thereby (the “UpHealth Business Combination”), including the merger of UpHealth Merger Sub with and into UpHealth, with UpHealth surviving the merger, and the issuance of Common Stock to UpHealth equity holders as merger consideration;
2.The Cloudbreak Business Combination Proposal-To approve and adopt the Cloudbreak Business Combination Agreement, dated as of November 20, 2020 (as subsequently amended on April 23, 2021 and as it may be amended and/or restated from time to time, the “Cloudbreak Business Combination Agreement” and, together with the UpHealth Business Combination Agreement, the “Business Combination Agreements”) by and among the Company, its wholly owned subsidiary, Cloudbreak Merger Sub, LLC (“Cloudbreak Merger Sub”), and Cloudbreak Health, LLC (“Cloudbreak”), a copy of which is attached to this proxy statement/prospectus as Annex B, and approve the transactions contemplated thereby (the “Cloudbreak Business Combination” and, together with the UpHealth Business Combination, the “Business Combinations”), including the merger of Cloudbreak Merger Sub with and into Cloudbreak, with Cloudbreak surviving the merger, and the issuance of Common Stock to Cloudbreak equity holders as merger consideration;
3.The NYSE Stock Issuance Proposal-To approve, for purposes of complying with applicable listing rules of the New York Stock Exchange (the “NYSE”), the issuance of more than 20% of the Company’s outstanding GigCapital2 Common Stock (as defined below) in connection with the Business Combinations, and the transactions contemplated by the PIPE Subscription Agreements and the Convertible Note Subscription Agreements (each as defined below) including up to 110,000,000 shares of GigCapital2 Common Stock to the UpHealth and Cloudbreak equity holders, 3,000,000 shares of GigCapital2 Common Stock to the PIPE Investor and 22,173,913 shares of our GigCapital2 Common Stock upon conversion of the Convertible Notes (as defined below);
4.Classification of the Board of Directors Proposal-To provide for the classification of our board of directors (our “Board”) into three classes of directors with staggered terms of office and to make certain related changes;
5.Approval of Additional Amendments to Current Certificate of Incorporation in Connection with the Business Combinations Proposal-To approve certain additional changes, including but not limited to changing the post-combination company’s corporate name from “GigCapital2, Inc.” to “UpHealth, Inc.” and eliminating certain provisions specific to our status as a blank check company, which our Board believes are necessary to adequately address the needs of the post-combination company;
6.Amendment to Exclusive Forum Provision-To authorize amendments to the existing exclusive forum provision for certain stockholder litigation, to provide that U.S. federal district courts are the sole and exclusive forum for claims arising under the Securities Act;
7.The Incentive Plan Proposal-To approve the Incentive Plan, including the authorization of the initial share reserve under the Incentive Plan;
8.The Election of Directors Proposal-To elect, effective at Closing, nine directors to serve staggered terms on our board of directors until the 2022, 2023 and 2024 annual meetings of stockholders, respectively, and until their respective successors are duly elected and qualified;
9.Adjournment Proposal-To approve, if necessary, the adjournment of the Special Meeting to a later date or dates to permit further solicitation and votes of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the UpHealth Business Combination Proposal, the Cloudbreak Business Combination Proposal, the NYSE Stock Issuance Proposal, the Charter Amendment Proposals, the Incentive Plan Proposal or the Election of Directors Proposal. This proposal will only be presented at the Special Meeting if there are not sufficient votes to approve the UpHealth Business Combination Proposal, the Cloudbreak Business Combination Proposal the NYSE Stock Issuance Proposal, the Charter Amendment Proposals, the Incentive Plan Proposal or the Election of Directors Proposal.
|
| 2021-03-03 |
股东大会：
将于2021-03-08召开股东大会
会议内容 ▼▲
- 1.To amend (the “Extension Amendment”) the Company’s Amended and Restated Certificate of Incorporation (as amended by the Certificate of Amendment, dated December 8, 2020, our “charter”) to extend the date by which the Company must consummate a Business Combination (as defined below) (the “Extension”) from March 10, 2021 (the date which is 21 months from the closing date of the Company’s initial public offering of our units (the “IPO”)) to June 10, 2021 (the date which is 24 months from the closing date of the IPO) (the “Extended Date”).
|
| 2021-03-03 |
股东大会：
将于2021-03-10召开股东大会
会议内容 ▼▲
- 1.To amend (the “Extension Amendment”) the Company’s Amended and Restated Certificate of Incorporation (as amended by the Certificate of Amendment, dated December 8, 2020, our “charter”) to extend the date by which the Company must consummate a Business Combination (as defined below) (the “Extension”) from March 10, 2021 (the date which is 21 months from the closing date of the Company’s initial public offering of our units (the “IPO”)) to June 10, 2021 (the date which is 24 months from the closing date of the IPO) (the “Extended Date”).
|
| 2020-11-02 |
股东大会：
将于2020-12-03召开股东大会
会议内容 ▼▲
- 1.To amend (the “Extension Amendment”) the Company’s Amended and Restated Certificate of Incorporation (our “charter”) to extend the date by which the Company must consummate a Business Combination (as defined below) (the “Extension”) from December 10, 2020 (the date which is 18 months from the closing date of the Company’s initial public offering of our units (the “IPO”)) to March 10, 2021 (the date which is 21 months from the closing date of the IPO) (the “Extended Date”);
2.To elect five directors to serve as directors on the Company’s Board of Directors (the “Board”) until the 2021 annual meeting of stockholders or until their successors are elected and qualified;
3.To ratify the selection by our Audit Committee of BPM LLP (“BPM”) to serve as our independent registered public accounting firm for the year ending December 31, 2020;
4.To consider such other matters as may properly come before the annual meeting or any adjournment(s) or postponement(s) thereof.
|
| 2019-08-12 |
详情>>
内部人交易：
McDonough Tara M股份减少5000.00股
|